Wednesday, October 14, 2026

ServiceNow Buys Gartner's 'Most Innovative' Analytics Vendor as AI-Native BI Deals Accelerate

ServiceNow has acquired Pyramid Analytics, which Gartner ranked as the most innovative vendor in its category. The deal is part of a broader wave of enterprise software M&A targeting AI-embedded business intelligence platforms. JVP, Pyramid's lead investor since 2020, recorded four exits in Q1 2026 alone, including a 6x return on DealHub.

LM Salvado
LM Salvado

June 1, 2026

ServiceNow Buys Gartner's 'Most Innovative' Analytics Vendor as AI-Native BI Deals Accelerate
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

ServiceNow has acquired Pyramid Analytics, a business intelligence platform Gartner designated the most innovative vendor in its category.1 The deal marks one of the most closely watched exits in enterprise analytics, where AI-native architecture has become the primary acquisition driver.

Pyramid Analytics built its platform with AI embedded at the data model layer, not bolted on post-build. That distinction is increasingly what large enterprise software vendors are paying premiums to acquire.1

Jerusalem Venture Partners (JVP) led Pyramid's 2020 funding round and backed its international expansion through to exit.1 The firm recorded four separate M&A exits in Q1 2026, including a 6x return on DealHub, a revenue intelligence platform.1 The cluster of exits points to sustained buyer appetite for AI-embedded B2B SaaS, not a single opportunistic deal.

A second transaction reinforces the trend. Everpure acquired 1touch.io, a data intelligence company, in a deal analysts read as enterprise validation of AI-ready data infrastructure.1 Buyers are moving upstream — acquiring the pipes before the analytics layer commoditizes.

The strategic logic is consistent across both deals: large vendors lack the internal velocity to build AI-native tooling at the pace the market demands. Acquisition is faster than development, and the premium reflects time-to-capability, not just revenue.

The test for whether AI-native platforms systematically command higher multiples than non-AI SaaS peers will play out over the next 12 months as more deals close and disclose terms.1 The Q1 2026 volume suggests the pipeline is active. ServiceNow's move gives the clearest public signal yet that top-tier BI vendors with genuine AI architecture — not retrofitted features — are the priority targets.

For enterprise software investors, the Pyramid exit resets the benchmark. Gartner-validated innovation combined with AI-native architecture now appears to be the formula acquirers are pricing above sector median.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com